Text Size
16350 studies found for:    T

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism
Conditions: Quality of Life;   Depression
Intervention: Drug: Triiodothyronine
2 Recruiting Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
Condition: Lymphoma, T-Cell, Peripheral
Intervention:
3 Recruiting A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808
Condition: Alzheimers Disease
Intervention: Radiation: [F18] T808
4 Recruiting CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study
Conditions: Peripheral T-cell Lymphoma NOS;   Anaplastic Large Cell Lymphoma, ALK-Negative;   Angioimmunoblastic T-cell Lymphoma;   Hepatosplenic Gamma/ Delta T-cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Gemcitabine;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisolone;   Drug: methylprednisolone;   Drug: Cisplatin
5 Completed Assessment of the Clinical Efficacy and Acceptability of Think Positive (T+) in Diabetes Management
Condition: Diabetes (Insulin-requiring, Type 1 or Type 2)
Intervention: Device: Mobile phone telehealth application: Think Positive (T+)
6 Recruiting Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia;   Relapsed T-Cell Lymphoblastic Lymphoma
Interventions: Drug: Nelarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Filgrastim
7 Recruiting Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).
Condition: Mantle Cell Lymphoma Refractory
Interventions: Drug: Torisel and R-CHOP;   Drug: Torisel and R-FC;   Drug: Torisel and R-DHA
8 Recruiting Efficacy Study of T2 Versus AZA to Maintain Clinical and Endoscopic Remission in Postoperative Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: T2;   Drug: Azathioprine
9 Recruiting Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Phase Chronic Myelogenous Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Biological: WT1-sensitized T cells;   Biological: aldesleukin;   Other: laboratory biomarker analysis
10 Not yet recruiting T2 Mapping of the Heart in Acute Myocardial Infarction Population for the Prediction of Short Term Major Adverse Cardiovascular Events
Condition: Myocardial Infarction, Acute
Intervention:
11 Recruiting CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells
Condition: Liver Metastases
Intervention: Biological: anti-CEA 2nd generation designer T cells
12 Not yet recruiting Phase I Trial: T4 Immunotherapy of Head and Neck Cancer
Condition: Head and Neck Cancer
Intervention: Other: Intra-tumoral T4 immunotherapy
13 Completed
Has Results 		Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children?
Condition: Low T3 Syndrome
Interventions: Drug: Oral T3 Low dose;   Drug: Placebo;   Drug: Oral T3 high dose
14 Active, not recruiting A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma
Conditions: Adult T-cell Leukemia-Lymphoma;   Peripheral T-cell Lymphoma
Intervention: Drug: Lenalidomide
15 Completed Liothyronine (T3) for Bipolar Depression
Conditions: Depression;   Bipolar Disorder
Interventions: Drug: Liothyronine (T3);   Drug: placebo
16 Recruiting A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
Condition: Breast Cancer
Interventions: Drug: T-DM1;   Drug: Trastuzumab
17 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Conditions: Contiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: doxorubicin hydrochloride;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: prednisone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: mercaptopurine;   Drug: nelarabine;   Drug: asparaginase;   Drug: dexamethasone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
18 Recruiting Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Conditions: Leukemia;   Acute Lymphoblastic Leukemia
Intervention: Biological: gene-modified T cells targeted to B-ALL tumor cells
19 Not yet recruiting Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides
Conditions: CD30 Positive Cutaneous T Cell Lymphoma;   CD30 Positive Transformed Mycosis Fungoides
Intervention: Genetic: Genetically modified T cells # 1138
20 Completed Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina
Condition: Angina Pectoris
Intervention: Drug: T89
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years